Skip to main content
Atrás
ARVN logo

Arvinas, Inc.

Calidad de datos: 100%
ARVN
NASDAQ Healthcare Biotechnology
$10.92
▲ $0.63 (6.12%)
Cap. Mercado: 701.33M
Rango del Día
$10.39 $11.00
Rango de 52 Semanas
$5.90 $14.51
Volumen
547,472
Promedio 50D / 200D
$12.71 / $10.01
Cierre Anterior
$10.29

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -8.7 0.3
P/B 1.6 3.0
ROE % -16.2 3.7
Net Margin % -30.8 3.8
Rev Growth 5Y % 48.8 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$12.50 +14.5%
Low: $6.00 High: $18.00
EPS Futuro
-$3.32
Ingresos Est.
93.17M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 -$0.63
-$1.30 – -$0.17
 276.89M 6
FY2029 -$1.87
-$3.84 – -$0.49
 208.60M 6
FY2028 -$2.14
-$3.75 – $2.83
 160.81M 8

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-24 -$0.51 -$1.10 -114.2%
2025-11-05 -$0.75 -$0.48 +36.0%
2025-08-06 -$0.87 -$0.84 +3.4%
2025-05-01 -$0.86 $1.14 +232.6%
2025-02-11 -$1.07 -$0.63 +41.1%
2024-10-30 -$0.88 -$0.68 +22.7%
2024-07-30 -$0.72 -$0.49 +31.9%
2024-05-07 -$1.48 -$0.97 +34.5%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 48.78% annually over 5 years — strong growth
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -275.70M
PEG of 0.18 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 49.08%
Capital efficient — spends only 0.72% of revenue on capex

Crecimiento

Revenue Growth (5Y)
48.78%
Revenue (1Y)-0.30%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-16.23%
ROIC-19.48%
Net Margin-30.77%
Op. Margin-43.75%

Seguridad

Debt / Equity
0.02
Current Ratio4.92
Interest Coverage0.00

Valoración

P/E Ratio
-8.68
Forward P/EN/A
P/B Ratio1.62
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0.30% Revenue Growth (3Y) 82.90%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 48.78% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 262.60M Net Income (TTM) -80.80M
ROE -16.23% ROA -11.26%
Gross Margin 98.02% Operating Margin -43.75%
Net Margin -30.77% Free Cash Flow (TTM) -275.70M
ROIC -19.48% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 4.92
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8.68 Forward P/E N/A
P/B Ratio 1.62 P/S Ratio 2.67
PEG Ratio 0.18 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 7.53 Fwd Earnings Yield N/A
FCF Yield -39.31%
Market Cap 701.33M Enterprise Value 566.93M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 262.60M 263.40M 78.50M 131.40M 53.60M
Net Income -80.80M -198.90M -367.30M -282.50M -191.00M
EPS (Diluted) -1.28 -2.77 -6.62 -5.31 -3.82
Gross Profit 257.40M 263.40M 78.50M 131.40M 53.60M
Operating Income -114.90M -250.20M -401.50M -263.20M -188.40M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 717.90M 1.09B 1.30B 1.27B 1.58B
Total Liabilities 284.00M 529.70M 644.60M 703.90M 799.90M
Shareholders' Equity 433.90M 561.70M 660.00M 564.90M 781.70M
Total Debt 8.50M 9.70M 3.20M 5.50M 5.00M
Cash & Equivalents 142.90M 100.50M 311.70M 81.30M 108.30M
Current Assets 700.70M 1.07B 1.28B 1.24B 1.55B
Current Liabilities 142.50M 229.80M 257.10M 295.10M 261.70M